Fate Therapeutics (FATE) Equity Ratio (2012 - 2026)

Fate Therapeutics has reported Equity Ratio for 15 years, with the latest figure at 0.63 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 12.81% year-over-year to 0.63; the trailing twelve-month figure through Mar 2026 stood at 0.63 (down 12.81% YoY), and the FY2025 full-year result was 0.65, down 10.18% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.63, down from 0.65 in the prior quarter.
• The five-year high for Equity Ratio was 0.76 in Q1 2023, with the low at 0.63 in Q1 2026.
• Historically, Equity Ratio has averaged 0.71 across 5 years, with a median of 0.72 in 2025.
• Annual changes were most pronounced in 2023 — Equity Ratio rose 7.15% — and 2026, when it decreased 12.81%.
• Fate Therapeutics' Equity Ratio stood at 0.69 in 2022, then climbed by 6.11% to 0.73 in 2023, then fell by 0.62% to 0.72 in 2024, then declined by 10.18% to 0.65 in 2025, then decreased by 2.91% to 0.63 in 2026.
• The last three Equity Ratio figures came in at 0.63 (Q1 2026), 0.65 (Q4 2025), and 0.68 (Q3 2025), per Business Quant data.